Mineralys Therapeutics to Announce Second Quarter 2024 Financial Results’
RADNOR, Pa. Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for hypertension, chronic kidney disease (CKD), and other conditions driven by dysregulated aldosterone, has announced that it will release its financial results for the second quarter of 2024 on Tuesday, August 13, 2024. This announcement will occur after the financial markets have closed for the day.
The company has scheduled a conference call to discuss the financial results. This event will presumably address the company’s progress in its clinical stage endeavors, including developments involving its pipeline drugs aimed at managing hypertension and CKD. Stakeholders, analysts, and interested parties are anticipated to gain valuable insights into Mineralys Therapeutics’ financial health and strategic direction from this briefing. The detailed financial report will examine the company’s fiscal performance for the quarter that ended on June 30, 2024.
Mineralys Therapeutics continues to focus on revolutionizing the treatment landscape for diseases associated with dysregulated aldosterone, a hormone known to impact blood pressure and fluid balance. This announcement is part of an ongoing commitment to maintain transparency with investors and provide regular updates on the company’s financial standing and developmental milestones. The forthcoming report and conference call will offer an in-depth look at the company’s recent achievements and future s in the biopharmaceutical realm.
Comments